ClinicalTrials.gg

Program

boserolimab

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms, led by Merck.

Furthest: phase 2, since Nov 14, 20195 company-led studies, 1 open or runningNext primary completion: Feb 13, 2032 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck51 open or runningphase 2since Nov 14, 2019Jan 4, 2018Feb 13, 2032phase 2 · NCT04165070

Also a collaborator on its studies: Daiichi Sankyo.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 4, 2018First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03396445 · 182 enrolled · United States, Chile, Israel and more
  2. Nov 14, 20192 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT04165096, NCT04165070
  3. Jun 9, 2021Phase 2 study in Small Cell Lung CarcinomaNCT04924101 · 122 enrolled · United States, Austria, Canada and more
  4. Feb 11, 2025Phase 2 study in Triple Negative Breast NeoplasmsNCT06829199 · United States, Taiwan

Ahead

  1. Feb 13, 2032Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04165070

TargetBeta

CD27 →read by rule
“A humanized agonistic monoclonal antibody targeting the cell surface antigen CD27, ”NCIt, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06829199Triple Negative Breast Neoplasms · United States, Taiwan2WithdrawnJan 18, 20290
NCT04924101Small Cell Lung Carcinoma · United States, Austria, Canada and more2CompletedJun 23, 2025122
NCT04165096Carcinoma, Non-Small-Cell Lung · United States, Hungary, Israel and more2CompletedApr 30, 2025128
NCT04165070Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more2RecruitingFeb 13, 2032450
NCT03396445Carcinoma, Non-Small-Cell Lung · United States, Chile, Israel and more1CompletedSep 27, 2024182

How it is read

Names in the registry

  • “Boserolimab”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.